Company Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.
pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities.
The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.
ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 624 |
| CEO | Adam S. Grossman |
Contact Details
Address: C/o Adma Biologics, Inc., 465 State Route 17 Ramsey, New Jersey 07446 United States | |
| Phone | (201) 478-5552 |
| Website | admabiologics.com |
Stock Details
| Ticker Symbol | ADMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001368514 |
| CUSIP Number | 000899104 |
| ISIN Number | US0008991046 |
| Employer ID | 56-2590442 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam S. Grossman | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder and Vice Chairman of the Board |
| Brian Lenz CPA | Executive Vice President, Chief Financial Officer and GM of ADMA BioCenters |
| Kaitlin Kestenberg | Chief Operating Officer and Senior Vice President of Compliance |
| Drew Pantello | Vice President of Marketing and Corporate Development |
| Cindy Petersen | Executive Director of Human Resources |
| Skyler Bloom | Senior Director of Business Development and Corporate Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | ARS | Filing |
| Apr 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 144 | Filing |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 5, 2024 | 8-K | Current Report |